Who
Kevin Joseph Fitzgerald
Director
Company insider
Files Form 4 as: Director, Ovid Therapeutics; CSO & EVP, Head of Research, Alnylam Pharmaceuticals.
In numbers
- Trades disclosed
- 242
- Buys
- 0
- Sells
- 20
- Bought
- $0
- Sold
- $23.8M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 6 Oct 2021
- Last trade
- 7 Apr 2026
- Last filed
- 9 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Apr 2026filed 9 Apr 2026 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code A | $45K17,578 at $2.56 | filing |
| 7 Apr 2026filed 9 Apr 2026 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code A | $45K17,578 at $2.56 | filing |
| 5 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $75K233 at $323.25 | filing |
| 5 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $48K148 at $324.60 | filing |
| 5 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $50K153 at $326.24 | filing |
| 5 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $40K124 at $321.81 | filing |
| 5 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $75K233 at $323.25 | filing |
| 5 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $48K148 at $324.60 | filing |
| 5 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $50K153 at $326.24 | filing |
| 5 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $40K124 at $321.81 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $9,25229 at $319.03 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $8,96028 at $320.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $19K59 at $320.81 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $25K79 at $321.82 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $31K96 at $323.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $68K210 at $323.84 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $24K75 at $324.88 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $19K57 at $325.67 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $9,25229 at $319.03 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $8,96028 at $320.01 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) and TScan Therapeutics (NASDAQ:TCRX) Critical SurveyALNY · themarketsdaily.com · 20 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Wells Fargo & CompanyALNY · tickerreport.com · 17 Oct 2026Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyALNY · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Kevin Joseph Fitzgerald; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.